Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Tyrosine Kinase Inhibitors × Tumor-Agnostic × Clear all
NCT01098500 2017-05-30

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

GlaxoSmithKline

Completed
3,800 enrolled 19 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡